Quarterly ResultMay 7, 2026, 04:07 PM
Alector Q1 Net Loss $22.9M; Cash $206.5M provides runway through 2027
AI Summary
Alector, Inc. reported its first quarter 2026 financial results, with a net loss of $22.9 million, a significant reduction from the prior year. The company holds $206.5 million in cash, cash equivalents, and investments, projected to fund operations at least through 2027. While Alector continues to advance its Alector Brain Carrier (ABC) platform and related programs for neurodegenerative diseases, it announced the discontinuation of the global Phase 2 clinical trial for nivisnebart in early Alzheimer's disease following a futility analysis.
Key Highlights
- Alector reported a Q1 2026 net loss of $22.9 million, or $0.21 per share, compared to $40.5 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $206.5 million as of March 31, 2026.
- Management anticipates the cash position provides a runway at least through 2027.
- Q1 2026 collaboration revenue was $1.0 million, down from $3.7 million in Q1 2025.
- Q1 2026 R&D expenses decreased to $17.9 million from $33.6 million in Q1 2025.
- Q1 2026 G&A expenses decreased to $8.1 million from $14.7 million in Q1 2025.
- The global Phase 2 clinical trial for nivisnebart (AL101/GSK4527226) was discontinued.
- Alector targets an IND submission for AL037/AL137 in Q1 2027.